摘要
目的 探讨DNA拓扑异构酶Ⅱ（TopoⅡ）在化疗后患者骨肉瘤组织中的表达.方法 对30例骨肉瘤患者术前进行2个疗程化疗,手术切除肿瘤组织,通过免疫组织化学法检测骨肉瘤组织中TopoⅡ的表达,分析其与临床病理因素的关系.结果 30例骨肉瘤组织中TopoⅡ阳性表达8例（26.7％）.TopoⅡ蛋白表达与患者的年龄、性别、肿瘤的恶性程度、发生部位、有无转移及Enneking分期均无关（P＞0.05）,21例生存患者中,TopoⅡ蛋白阴性18例,9例死亡患者中,TopoⅡ蛋白阴性4例,二者阴性表达率差异有统计学意义（P＜0.05）.结论 TopoⅡ低表达的骨肉瘤患者可能预后较差.
Objective To probe into the content of DNA Topo Ⅱ in osteosarcoma after chemotherapy.Methods 30 patients with osteosarcoma received two courses of chemotherapy treatment before the surgical resection of the tumor tissue.Then immunohistochemistry was used to detect the content of Topo Ⅱ in tissues and detected its relationship in pathology.Results There were 8 out of 30 cases in which Topo Ⅱ was presented positive in osteosarcoma （26.7 %）.The protein content of Topo Ⅱ was unrelated to the patient＆#39; s age,gender,degree of tumor malignancy,tumor location and translocation or Enneking staging （P 〉 0.05）,but related to patients survival rate （P 〈 0.05）.Conclusion Patients with lower expression of Topo Ⅱ are more likely to have poor prognosis.
出处
《肿瘤研究与临床》
CAS
2014年第10期689-690,694,共3页
Cancer Research and Clinic
关键词
骨肉瘤
DNA拓扑异构酶类
Ⅱ型
肿瘤转移
抗药性
肿瘤
预后
Osteosarcoma
DNA topoisomerases,type Ⅱ
Neoplasm metastasis
Drug resistance,neoplasm
Prognosis
